Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024)
Relay Therapeutics (RLAY) posted quarterly Total Non-Current Liabilities of $93.5 million for Q4 2024, up 18.7% year-over-year from $78.8 million in Q1 2024, and up 2.97% quarter-over-quarter from $90.8 million in Q2 2024.
Powered by 
Analysis
Relay Therapeutics (RLAY) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Relay Therapeutics (RLAY) has reported Total Non-Current Liabilities for 5 consecutive years, with $93.5 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities rose 18.7% year-over-year to $93.5 million; the TTM figure through Dec 2024 stood at $93.5 million (up 18.7% YoY), while the FY2024 annual figure was $93.5 million, up 18.7% from the prior year.
- Total Non-Current Liabilities advanced to $93.5 million in Q4 2024 per RLAY's latest filing, from $90.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $126.0 million in Q3 2022 and bottomed at $36.5 million in Q4 2020.
- Historically, Total Non-Current Liabilities has averaged $83.8 million across 5 years, with a median of $84.3 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 151.74% — and 2023, when it plunged 32.77%.
- Relay Therapeutics' Total Non-Current Liabilities stood at $36.5 million in 2020, then jumped by 65.25% to $60.4 million in 2021, then jumped by 94.07% to $117.2 million in 2022, then slumped by 32.77% to $78.8 million in 2023, then increased by 18.7% to $93.5 million in 2024.
- Business Quant data shows RLAY's Total Non-Current Liabilities at $93.5 million in Q4 2024, $90.8 million in Q2 2024, and $84.3 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Relay Therapeutics | 3.87 Bn | 3.87 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 93.50 Mn |
| Jun 30, 2024 | 90.81 Mn |
| Mar 31, 2024 | 84.30 Mn |
| Dec 31, 2023 | 78.77 Mn |
| Sep 30, 2023 | 100.56 Mn |
| Jun 30, 2023 | 122.67 Mn |
| Mar 31, 2023 | 122.77 Mn |
| Dec 31, 2022 | 117.18 Mn |
| Sep 30, 2022 | 126.03 Mn |
| Jun 30, 2022 | 63.92 Mn |
| Mar 31, 2022 | 62.25 Mn |
| Dec 31, 2021 | 60.38 Mn |
| Sep 30, 2021 | 50.06 Mn |
| Jun 30, 2021 | 47.41 Mn |
| Dec 31, 2020 | 36.54 Mn |